RMD240816C200000
- 26.10
- +2.80+12.02%
ResMed Newsroom
Morgans Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Price Target Raised to $206.00/Share From $204.00 by RBC Capital
RBC Adjusts ResMed's Price Target to $206 From $204, Keeps Sector Perform Rating
BofA Securities Maintains ResMed(RMD.US) With Buy Rating
Oppenheimer Remains a Hold on Resmed (RMD)
Oppenheimer Maintains ResMed(RMD.US) With Hold Rating
ResMed Analyst Ratings
KeyBanc Maintains ResMed(RMD.US) With Buy Rating
Needham Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $236
Resmed's Strong Financial and Market Performance Merits a Buy Rating
KeyBanc Keeps Their Buy Rating on Resmed (RMD)
Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) Receives a Hold From Citi
ResMed Price Target Raised 1.6% to A$35.40/Share by Macquarie
ResMed Price Target Raised to $204.00/Share From $200.00 by RBC Capital
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $204
ResMed Analyst Ratings
RBC Raises Price Target on ResMed to $204 From $200, Keeps Sector Perform Rating
UBS Adjusts ResMed Price Target to $210 From $195, Maintains Neutral Rating
ResMed, Inspire Medical Slump After Lilly's Positive Zepbound Data; Citi Downgrades
ResMed Analyst Ratings